Literature DB >> 21217175

Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

Stanley A Plotkin1.   

Abstract

A vaccine against Lyme disease was licensed in the United States in 1998 but was subsequently removed from the market because of lack of sales. I believe that the poor acceptance of the vaccine was based on tepid recommendations by the Centers for Disease Control and Prevention (CDC), undocumented and probably nonexistent safety issues, and insufficient education of physicians. A new vaccine is feasible but will not be developed unless there is a demand by infectious diseases specialists, epidemiologists, authorities in affected states and the public that is evident to manufacturers. The fact that there is no vaccine for an infection causing ∼20,000 annual cases is an egregious failure of public health.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217175     DOI: 10.1093/cid/ciq119

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease.

Authors:  Vince Pozsgay; Joanna Kubler-Kielb; Bruce Coxon; Adriana Marques; John B Robbins; Rachel Schneerson
Journal:  Carbohydr Res       Date:  2011-05-03       Impact factor: 2.104

2.  New vaccines - which ones should we choose?

Authors:  Joan Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  Dengue vaccines: the road to failure or to success?

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

4.  A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Authors:  Nina Wressnigg; P Noel Barrett; Eva-Maria Pöllabauer; Maria O'Rourke; Daniel Portsmouth; Michael G Schwendinger; Brian A Crowe; Ian Livey; Thomas Dvorak; Bernhard Schmitt; Markus Zeitlinger; Herwig Kollaritsch; Meral Esen; Peter G Kremsner; Tomas Jelinek; Roland Aschoff; Roland Weisser; Ingomar F K Naudts; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

5.  Lyme Disease in Humans.

Authors:  Justin D Radolf; Klemen Strle; Jacob E Lemieux; Franc Strle
Journal:  Curr Issues Mol Biol       Date:  2020-12-11       Impact factor: 2.081

Review 6.  Hamster and murine models of severe destructive Lyme arthritis.

Authors:  Erik Munson; Dean T Nardelli; Brian K Du Chateau; Steven M Callister; Ronald F Schell
Journal:  Clin Dev Immunol       Date:  2012-02-22

7.  TickNET-A Collaborative Public Health Approach to Tickborne Disease Surveillance and Research.

Authors:  Paul Mead; Alison Hinckley; Sarah Hook; C Ben Beard
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

8.  Immunization with a Borrelia burgdorferi BB0172-derived peptide protects mice against lyme disease.

Authors:  Christina M Small; Dharani K Ajithdoss; Aline Rodrigues Hoffmann; Waithaka Mwangi; Maria D Esteve-Gassent
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

Review 9.  Vaccination against Lyme disease: past, present, and future.

Authors:  Monica E Embers; Sukanya Narasimhan
Journal:  Front Cell Infect Microbiol       Date:  2013-02-12       Impact factor: 5.293

10.  Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Authors:  Michael G Schwendinger; Maria O'Rourke; Andreas Traweger; Helga Savidis-Dacho; Andreas Pilz; Daniel Portsmouth; Ian Livey; P Noel Barrett; Brian A Crowe
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.